Security
Citius Pharmaceuticals, Inc. Common Stock · CTXR
CTXRNASDAQCommon stockCurrentCIK 1506251Updated Oct 27, 2026
Name history
Trail One, Inc. · through Sep 18, 2014TrailOne, Inc. · through Jan 21, 2011
CTXR price & chart
Loading TradingView…
NASDAQ:CTXR on TradingView ↗About the company
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I - III CTCL after at least one prior systemic therapy. Management estimates the initial CTCL market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets, and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology’s competitive positioning. For more information, please visit www.citiusonc.com.
In the news
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update News provided by Citius Oncology, Inc. Dec 23, 2025, 16:30 ET Share this article Share to X Share this article Share to X Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025 Completed $36 ↗
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update News provided by Citius Pharmaceuticals, Inc. Dec 23, 2025, 16:30 ET Share this article Share to X Share this article Share to X Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, ↗
Recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A - filed by CVI Investments, Inc. regarding Citius Pharmaceuticals, Inc.
Show 5 more recent filings
Other Events
Items 8.01, 9.01
EFFECT filing
Other Events
Items 8.01, 9.01
S-3 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 142,255,198Source | 127,676,859Source | 97,090,579Source | 132,540,579Source | 121,481,411Source | 90,711,369Source | 140,391,730Source | 120,703,457Source | 130,938,025Source | 116,651,751Source | 103,611,150Source | 113,999,302Source |
| Property, Plant and Equipment, NetUSD | — | — | — | — | — | 275Source | — | — | — | — | 1,432Source | 4,100Source |
| GoodwillUSD | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 17,007,523Source | 6,089,126Source | 17,911,192Source | 4,590,174Source | 26,410Source | 12,559,607Source | 7,721,393Source | 1,100,079Source | 4,252,290Source | 3,251,880Source | 26,480,928Source | 41,711,690Source |
| Inventory, NetUSD | 22,625,945Source | 17,208,967Source | — | 22,659,590Source | 15,339,253Source | — | 22,639,342Source | 14,381,369Source | 22,286,693Source | — | — | — |
| Assets, CurrentUSD | 43,331,363Source | 24,611,269Source | 28,005,789Source | 31,685,701Source | 18,374,454Source | 21,573,731Source | 37,945,133Source | 18,327,187Source | 27,934,473Source | 14,220,646Source | 34,370,434Source | 44,564,270Source |
| Operating Lease, Right-of-Use AssetUSD | 753,039Source | 880,732Source | 299,932Source | 794,518Source | 922,099Source | 352,505Source | 835,177Source | 191,412Source | 818,694Source | 246,247Source | 454,426Source | 646,074Source |
| Other Assets, NoncurrentUSD | 98,170,796Source | 102,184,858Source | — | 100,060,360Source | 102,184,858Source | — | 101,611,420Source | 102,184,858Source | 102,184,858Source | 102,184,858Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 66,346,742Source | 60,115,929Source | 10,806,300Source | 63,456,026Source | 57,905,619Source | 10,744,418Source | 46,923,760Source | 51,783,998Source | 53,410,425Source | 42,549,921Source | 12,179,662Source | 10,573,057Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 27,452Source | 14,475Source | 180,725Source | 22,376Source | 8,761Source | 159,095Source | 22,376Source | 7,727Source | 18,068Source | 7,247Source | 158,858Source | 146,211Source |
| Additional Paid in CapitalUSD | 343,704,577Source | 295,888,916Source | 276,083,228Source | 329,775,214Source | 282,705,620Source | 259,214,194Source | 326,960,700Source | 276,538,816Source | 306,336,239Source | 271,440,421Source | 252,903,629Source | 232,368,121Source |
| Retained Earnings (Accumulated Deficit)USD | -277,118,897Source | -230,844,841Source | -190,580,054Source | -268,256,054Source | -222,054,969Source | -180,006,718Source | -247,024,914Source | -211,138,464Source | -238,804,129Source | -201,370,218Source | -162,231,379Source | -129,688,467Source |
| Stockholders' Equity Attributable to ParentUSD | 66,613,132Source | 65,058,550Source | 85,683,899Source | 61,541,536Source | 60,659,412Source | 79,366,571Source | 79,958,162Source | 65,408,079Source | 67,550,178Source | 70,077,450Source | 90,831,108Source | 102,825,865Source |
| Liabilities and EquityUSD | 142,255,198Source | 127,676,859Source | 97,090,579Source | 132,540,579Source | 121,481,411Source | 90,711,369Source | 140,391,730Source | 120,703,457Source | 130,938,025Source | 116,651,751Source | 103,611,150Source | 113,999,302Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 51,649,351Source | 51,842,452Source | 4,152,070Source | 55,015,569Source | 49,876,642Source | 4,173,520Source | 38,207,120Source | 44,805,958Source | 44,914,740Source | 35,814,803Source | 5,778,997Source | 4,530,012Source |
| Operating Lease, Liability, CurrentUSD | 176,170Source | 114,694Source | 235,581Source | 171,495Source | 145,098Source | 229,733Source | 148,006Source | 204,569Source | 88,348Source | 241,547Source | 218,380Source | 196,989Source |
| Accounts Payable, CurrentUSD | 8,037,899Source | 10,094,042Source | 1,663,336Source | 9,453,803Source | 9,368,234Source | 2,669,507Source | 11,021,412Source | 7,364,120Source | 13,693,692Source | 4,927,211Source | 2,927,334Source | 1,165,378Source |
| Operating Lease, Liability, NoncurrentUSD | 590,787Source | 766,957Source | 84,430Source | 636,667Source | 786,697Source | 145,098Source | 681,640Source | — | 724,925Source | 21,318Source | 262,865Source | 481,245Source |
| Deferred Income Tax Liabilities, NetUSD | 7,696,443Source | 7,506,520Source | 6,569,800Source | 7,803,790Source | 7,242,280Source | 6,425,800Source | 8,035,000Source | 6,978,040Source | 7,770,760Source | 6,713,800Source | 6,137,800Source | 5,561,800Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 9,295,324Source | 2,502,380Source | 600,380Source | 7,543,017Source | 2,916,380Source | 600,380Source | 13,509,808Source | 3,511,380Source | 9,977,422Source | 4,024,380Source | 600,380Source | 600,380Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 25,913,962Source | 8,523,675Source | 550,485Source | 24,138,264Source | 8,779,244Source | 151,204Source | 4,693,307Source | 6,242,178Source | 4,190,253Source | 17,027Source | 476,300Source | 1,405,394Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 7,770,760Source | 6,713,800Source | 6,137,800Source | 5,561,800Source |
| Accounts Receivable, after Allowance for Credit Loss, Current | —Source | — | — | —Source | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -11,919,260Source | -9,203,872Source | -28,109,746Source | -11,511,505Source | -9,393,889Source | -10,281,246Source | -39,740,269Source | -39,425,839Source | -32,542,912Source | -33,640,646Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 3,810,665Source | 2,719,674Source | 3,788,275Source | 2,702,031Source | 4,280,227Source | 2,524,824Source | 10,836,291Source | 11,839,678Source | 6,616,705Source | 3,905,954Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 352,649Source | 6,112,603Source | 12,649,207Source | 2,133,871Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -2,672,280Source | 2,436,909Source | 8,766,481Source | 1,999,877Source | 1,761,956Source | -111,717Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 264,240Source | 264,240Source | 1,056,960Source | 576,000Source | 576,000Source | 576,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -13,008,822Source | -4,725,852Source | -26,552,738Source | -28,201,375Source | -29,060,212Source | -28,361,256Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -4,400,000Source | — | -5,750,000Source | -5,000,000Source | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 20,877,925Source | 2,574,051Source | 33,303,148Source | 9,972,327Source | 13,829,450Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 17,007,523Source | 6,089,126Source | 4,590,174Source | 26,410Source | 7,721,393Source | 1,100,079Source | 4,252,290Source | 3,251,880Source | 26,480,928Source | 41,711,690Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 14,460Source | — | 187,389Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 3,061,763Source | 1,668,267Source | 2,702,031Source | — | 2,524,824Source | 10,836,291Source | 11,839,678Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | 1,432Source | 2,668Source | 2,923Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | 2,387,842Source | — | — |
| General and Administrative ExpenseUSD | — | — | 6,149,173Source | 4,447,008Source | 26,391,101Source | 4,792,122Source | 5,720,727Source | 5,387,752Source | 18,532,843Source | 18,249,402Source | 15,295,584Source | 11,754,609Source |
| GoodwillUSD | — | — | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source | 9,346,796Source |
| Income Tax Expense (Benefit)USD | — | — | -107,347Source | 264,240Source | -231,210Source | 264,240Source | 264,240Source | 264,240Source | 1,056,960Source | 576,000Source | 576,000Source | 576,000Source |
| InterestExpenseNonoperatingUSD | — | — | 231,732Source | 172,262Source | 33,031Source | — | 155,538Source | — | 267,782Source | — | — | — |
| Investment Income, InterestUSD | — | — | 116,691Source | 20,637Source | 53,584Source | 13,413Source | 45,097Source | 22,608Source | 110,081Source | 758,000Source | 1,179,417Source | 251,399Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | — | — | -11,511,505Source | — | — | — | — | -32,542,912Source | -33,640,646Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -3,056,417Source | -414,000Source | -6,878,606Source | -595,000Source | -1,173,104Source | -513,000Source | -2,306,358Source | -287,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -8,862,843Source | -8,789,872Source | -21,231,140Source | -10,916,505Source | -8,220,785Source | -9,768,246Source | -37,433,911Source | -40,186,151Source | -33,694,120Source | -33,640,646Source |
| Nonoperating Income (Expense)USD | — | — | -294,533Source | -151,625Source | 3,853,830Source | 13,413Source | -110,441Source | 22,608Source | -157,701Source | 3,145,842Source | 4,765,106Source | — |
| Operating ExpensesUSD | — | — | 12,734,019Source | 8,788,007Source | 33,533,206Source | 11,260,678Source | 12,174,111Source | 10,039,614Source | 38,525,608Source | 41,995,681Source | 36,732,018Source | 33,316,045Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 16,483Source | 4,870Source | 39,054Source | 30,644Source | 47,176Source | 62,068Source |
| Other Operating Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | 251,399Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 20,877,925Source | 2,574,051Source | 32,303,148Source | 252,140Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | 31,267Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | — | 90,000Source |
| Amortization of Debt Issuance Costs | — | — | —Source | — | — | — | — | — | — | — | — | — |
| Gain (Loss) on Sale of Investments | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Payments of Financing Costs | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -11,732,074Source | -8,788,007Source | -32,194,786Source | -11,260,678Source | -9,019,208Source | -10,039,614Source | -38,525,608Source | -41,995,681Source | -36,732,018Source | -33,316,045Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -12,026,607Source | -8,939,632Source | -28,340,956Source | -11,247,265Source | -9,129,649Source | -10,017,006Source | -38,683,309Source | -38,849,839Source | -31,966,912Source | -33,064,646Source |
| Income Tax Expense (Benefit)USD | — | — | -107,347Source | 264,240Source | -231,210Source | 264,240Source | 264,240Source | 264,240Source | 1,056,960Source | 576,000Source | 576,000Source | 576,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -3,056,417Source | -414,000Source | -6,878,606Source | -595,000Source | -1,173,104Source | -513,000Source | -2,306,358Source | -287,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | — | — | -11,511,505Source | — | — | — | — | -32,542,912Source | -33,640,646Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.34Source | -0.8Source | -0.95Source | -1.27Source | -0.38Source | -1.3Source | -3.38Source | -5.97Source | — | -0.23Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.34Source | -0.8Source | -0.95Source | -1.27Source | -0.38Source | -1.3Source | -3.38Source | -5.97Source | — | -0.23Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 26,169,589Source | 11,006,896Source | 22,376,427Source | 8,581,207Source | 21,495,274Source | 7,492,460Source | 11,065,225Source | 6,726,999Source | 151,294,729Source | 146,082,399Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 26,169,589Source | 11,006,896Source | 22,376,427Source | 8,581,207Source | 21,495,274Source | 7,492,460Source | 11,065,225Source | 6,726,999Source | 151,294,729Source | 146,082,399Source |
| Interest Expense (non-operating)USD | — | — | 231,732Source | 172,262Source | 33,031Source | — | 155,538Source | — | 267,782Source | — | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 6,149,173Source | 4,447,008Source | 26,391,101Source | 4,792,122Source | 5,720,727Source | 5,387,752Source | 18,532,843Source | 18,249,402Source | 15,295,584Source | 11,754,609Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | — | — | — | — | — | — | — | -0.22Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | — | — | — | — | — | — | — | -0.22Source | — |
| Interest Expense, DebtUSD | — | — | — | 11,507Source | — | — | — | — | 49,750Source | — | — | — |
| Investment Income, InterestUSD | — | — | 116,691Source | 20,637Source | 53,584Source | 13,413Source | 45,097Source | 22,608Source | 110,081Source | 758,000Source | 1,179,417Source | 251,399Source |
| Management Fee ExpenseUSD | — | — | — | — | — | — | — | — | 90,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -8,862,843Source | -8,789,872Source | -21,231,140Source | -10,916,505Source | -8,220,785Source | -9,768,246Source | -37,433,911Source | -40,186,151Source | -33,694,120Source | -33,640,646Source |
| Nonoperating Income (Expense)USD | — | — | -294,533Source | -151,625Source | 3,853,830Source | 13,413Source | -110,441Source | 22,608Source | -157,701Source | 3,145,842Source | 4,765,106Source | — |
| Operating ExpensesUSD | — | — | 12,734,019Source | 8,788,007Source | 33,533,206Source | 11,260,678Source | 12,174,111Source | 10,039,614Source | 38,525,608Source | 41,995,681Source | 36,732,018Source | 33,316,045Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 16,483Source | 4,870Source | 39,054Source | 30,644Source | 47,176Source | 62,068Source |
| Other ExpensesUSD | — | — | — | — | — | — | 135,000Source | — | 150,958Source | — | — | — |
| Other Operating Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | 251,399Source |
| Research and Development ExpenseUSD | — | — | 1,053,869Source | 1,621,325Source | 1,633,518Source | 3,766,525Source | 1,599,719Source | 2,127,038Source | 9,156,474Source | 11,906,601Source | 14,819,729Source | 17,655,482Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | — | 90,000Source |
| Total Revenue | — | — | —Source | — | —Source | — | —Source | — | — | — | — | — |
| Cost of Goods and Services Sold | — | — | —Source | — | —Source | — | —Source | — | — | — | — | — |
| Gross Profit | — | — | —Source | — | —Source | — | —Source | — | — | — | — | — |
| Interest Expense | — | — | —Source | — | — | — | — | — | — | — | — | — |
Offerings
Registration 333-296195
Filing attachments
ea030934501ex99-1.htm · 8-K · 2026-10-26
Exhibit 99.1 Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 CRANFORD, N.J., October 26, 2026 - Citius Oncology, Inc. (“Citius Oncology” or the “Company”) (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today announced preliminary, unaudited LYMPHIR® (denileukin diftitox-c…
Read attachment ↗ea030222701ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 ea030222701ex99-1.htm PRESS RELEASE, DATED AUGUST 14, 2026 Exhibit 99.1 Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update $7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR® $17 million in cash and cash equivalents as of June 30, 2026 Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide CRANFORD, N.J., August 14, 2026 - Citius Pharmaceuticals,…
Read attachment ↗ea030037301ex99-1.htm · 8-K · 2026-08-05
EX-99.1 2 ea030037301ex99-1.htm PRESS RELEASE, DATED AUGUST 5, 2026 Exhibit 99.1 Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR’s near-universal payer coverage expands market access Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds $400 million CRANFORD, N.J., August 5, 2026 - Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), an oncolog…
Read attachment ↗ea029290401ex99-1.htm · 8-K · 2026-06-01
EX-99.1 2 ea029290401ex99-1.htm PRESS RELEASE, DATED JUNE 1, 2026 Exhibit 99.1 Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR ® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-treated patient…
Read attachment ↗ea029103701ex99-1.htm · 8-K · 2026-05-15
EX-99.1 2 ea029103701ex99-1.htm PRESS RELEASE, DATED MAY 15, 2026 Exhibit 99.1 Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update $5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ® Citius Pharma raised $5 million in a registered direct offering; Citius Oncology secured up to $36.5 million in debt and equity financing Advanced patient access with payer coverage near 100% of commercial l…
Read attachment ↗ea028820301ex99-1.htm · 8-K · 2026-04-29
EX-99.1 2 ea028820301ex99-1.htm PRESS RELEASE, DATED APRIL 29, 2026 Exhibit 99.1 Citius Oncology Ships First International Order of LYMPHIR™ to Europe Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distribution by regional partners through Named Patient Programs in specific international markets CRANFORD, N.J., April 29, 2026 - Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and major…
Read attachment ↗